AstraZenecaAZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $508M | Put options by funds: $206M
6% more repeat investments, than reductions
Existing positions increased: 453 | Existing positions reduced: 428
9% less first-time investments, than exits
New positions opened: 96 | Existing positions closed: 106
3% less funds holding
Funds holding: 1,233 [Q1] → 1,193 (-40) [Q2]
9% less capital invested
Capital invested by funds: $37.6B [Q1] → $34.1B (-$3.55B) [Q2]
16.81% less ownership
Funds ownership: 32.59% [Q1] → 15.78% (-16.81%) [Q2]
48% less funds holding in top 10
Funds holding in top 10: 21 [Q1] → 11 (-10) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for AZN.
Financial journalist opinion
Based on 36 articles about AZN published over the past 30 days









